Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
8.71
+0.05 (0.58%)
At close: Dec 5, 2025, 4:00 PM EST
8.88
+0.17 (1.95%)
After-hours: Dec 5, 2025, 7:59 PM EST
Zevra Therapeutics Revenue
Zevra Therapeutics had revenue of $26.06M in the quarter ending September 30, 2025, with 605.36% growth. This brings the company's revenue in the last twelve months to $84.39M, up 244.60% year-over-year. In the year 2024, Zevra Therapeutics had annual revenue of $23.61M, down -14.02%.
Revenue (ttm)
$84.39M
Revenue Growth
+244.60%
P/S Ratio
5.63
Revenue / Employee
$1,430,305
Employees
59
Market Cap
490.35M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 23.61M | -3.85M | -14.02% |
| Dec 31, 2023 | 27.46M | 17.30M | 170.26% |
| Dec 31, 2022 | 10.16M | -18.49M | -64.53% |
| Dec 31, 2021 | 28.65M | 15.36M | 115.61% |
| Dec 31, 2020 | 13.29M | 449.00K | 3.50% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ZVRA News
- 4 days ago - Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD - GlobeNewsWire
- 15 days ago - Zevra Therapeutics, Inc. Announces CFO Transition - GlobeNewsWire
- 4 weeks ago - Zevra Therapeutics, Inc. (ZVRA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Zevra Reports Third Quarter 2025 Financial Results and Corporate Update - GlobeNewsWire
- 5 weeks ago - Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference - GlobeNewsWire
- 5 weeks ago - Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call - GlobeNewsWire
- 2 months ago - Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyrate) - GlobeNewsWire